Jeena Sikho Lifecare Limited (JSLL) — Announcement | 18 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company announces publication of Ayurvedic case studies in academic journal
💡 Investor Takeaway
These publications strengthen the company's credibility in Ayurvedic research and may enhance investor confidence in its scientific foundation.

Jeena Sikho Lifecare Limited announced that case studies authored by its medical professionals, including the Managing Director, have been published in the Academia Journal of Medicine and Prakriti. The publications highlight the company's Ayurvedic research and evidence-based clinical practice across kidney disease and other health conditions, reinforcing its commitment to integrative Ayurvedic approaches.

📄 View Original Announcement (PDF)

About Jeena Sikho Lifecare Limited (JSLL)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹6,347.42 Cr P/E: 26.9 ROE: 187.8% ROCE: 261.5% Div Yield: 0.88%

View full JSLL stock details →

📡 Get AI alerts when JSLL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JSLL — Free

📊 More JSLL filings

See all JSLL filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JSLL files new disclosures

Track JSLL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JSLL — Free

Free account · 2 AI queries/day